A Phase 4 interventional study of Triptorelin (GnRH agonists) and Hormone Replacement Therapy (HRT) in Deep Infiltrating Endometriosis (DIE) and Infertility, sponsored by Li-jun Ding. Recruiting at 1 site in China. Open to female participants aged 18 Years to 39 Years. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Li-jun Ding · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing triptorelin in Infertility — 4 open to participants now, 4 under way, 1 of them phase 3. triptorelin · Infertility.
Among the 25 studies testing triptorelin in Infertility, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is the only one that started in 2025, is one of 9 in phase 4, and was the 25th registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →4 of the 25 studies testing triptorelin in Infertility are open now, in 2 countries. Recruiting first, the newest first:
The University of Hong Kong · Sites in China
Ages 18–42 · Women only
Mansoura University · Sites in Egypt
Ages 20–38 · Women only
Mansoura University · Sites in Egypt
Ages 20–38 · Women only
By country, each count listing its studies:
triptorelin: first FDA approval 2000 (TRELSTAR). What it is approved for, and how studies give it, is on its page →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 39 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 9
First in 2003; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 120 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 166 across the 23 interventional studies. Of the 13 that completed or were terminated, 2 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 25 has an industry lead sponsor. The 10 most frequent:
Li-jun Ding is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Li-jun Ding has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
1 of the studies testing triptorelin in Infertility that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07696351Li-jun DingUltra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing triptorelin in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment. Gonadotropin-releasing hormone agonist pretreatment may suppress endometriotic lesions, reduce inflammation, and improve endometrial receptivity, but its benefit before frozen-thawed embryo transfer remains uncertain.
This randomized controlled study will evaluate whether ultra-long GnRH-a pretreatment before hormone replacement therapy improves clinical pregnancy outcomes in patients with deep infiltrating endometriosis undergoing their first frozen-thawed embryo transfer cycle. Eligible participants will be randomly assigned to either the GnRH-a pretreatment group or the control group. Participants in the GnRH-a group will receive two injections of long-acting GnRH-a before hormone replacement therapy for endometrial preparation, while participants in the control group will receive routine hormone replacement therapy alone.
The primary outcome is clinical pregnancy rate, defined as the presence of a gestational sac on transvaginal ultrasound 30 ± 3 days after embryo transfer. Secondary outcomes include implantation rate, ectopic pregnancy rate, early spontaneous abortion rate, ongoing pregnancy rate at 12 weeks of gestation, and delivery rate. Safety will be evaluated by recording adverse events after GnRH-a injection. The planned enrollment is 120 participants.
Deep infiltrating endometriosis is a severe subtype of endometriosis that may involve pelvic organs and is associated with infertility, impaired endometrial receptivity, chronic pelvic inflammation, reduced implantation, increased miscarriage risk, and poorer outcomes after assisted reproductive treatment. For patients with deep infiltrating endometriosis who require frozen-thawed embryo transfer, the optimal endometrial preparation strategy remains uncertain.
Gonadotropin-releasing hormone agonists may suppress ovarian estrogen production, inhibit the activity of endometriotic lesions, reduce inflammatory mediators, and potentially improve the endometrial environment before embryo transfer. However, current evidence regarding GnRH-a pretreatment before frozen-thawed embryo transfer in patients with endometriosis is inconsistent, and high-quality prospective randomized controlled studies are limited. This study is designed to evaluate whether ultra-long GnRH-a pretreatment improves pregnancy outcomes in patients with deep infiltrating endometriosis undergoing frozen-thawed embryo transfer.
This is a prospective, randomized, controlled, single-center clinical study. A total of 120 eligible participants will be enrolled. Participants must be younger than 40 years, diagnosed with deep infiltrating endometriosis by ultrasound at the study center, undergoing their first frozen-thawed embryo transfer cycle with hormone replacement therapy for endometrial preparation, and have at least one good-quality frozen embryo. Eligible participants will be randomly assigned in a 1:1 ratio to the experimental group or the control group.
Participants in the experimental group will receive ultra-long GnRH-a pretreatment before frozen-thawed embryo transfer. Long-acting GnRH-a will be administered on menstrual cycle days 2 to 4, followed by a second injection 28 to 30 days later. Hormone replacement therapy for endometrial preparation will begin 28 to 30 days after the second GnRH-a injection, followed by frozen-thawed embryo transfer according to routine clinical practice.
Participants in the control group will undergo routine hormone replacement therapy for endometrial preparation before frozen-thawed embryo transfer without GnRH-a pretreatment.
The primary outcome is clinical pregnancy rate, defined as the presence of a gestational sac detected by transvaginal ultrasound 30 ± 3 days after embryo transfer. Secondary outcomes include implantation rate, ectopic pregnancy rate, early spontaneous abortion rate, ongoing pregnancy rate at 12 weeks of gestation, and delivery rate. Additional pregnancy, obstetric, and neonatal outcomes may be followed according to the study protocol, including biochemical pregnancy, late spontaneous abortion, preterm birth, stillbirth, live birth, pregnancy complications, delivery outcomes, and birth weight.
Safety will be assessed by monitoring and recording adverse events after GnRH-a injection, including hot flashes, headache, sleep disturbance, vaginal bleeding or spotting, night sweats, and mood changes. Participants will be followed after embryo transfer and, if pregnancy occurs, through pregnancy and delivery according to the protocol-defined follow-up schedule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive ultra-long GnRH-a pretreatment before frozen-thawed embryo transfer. Long-acting GnRH-a will be administered on menstrual cycle days 2 to 4, followed by a second injection 28 to 30 days later. Hormone replacement therapy for endometrial preparation will begin 28 to 30 days after the second GnRH-a injection, followed by frozen-thawed embryo transfer according to routine clinical practice.
Drug: Triptorelin (GnRH agonists)
Participants in this group will undergo routine hormone replacement therapy for endometrial preparation before frozen-thawed embryo transfer without GnRH-a pretreatment.
Other: Hormone Replacement Therapy (HRT)
Long-acting GnRH-a pretreatment will be administered before hormone replacement therapy for endometrial preparation. Participants will receive two injections of triptorelin 3.75 mg: the first on menstrual cycle days 2 to 4 and the second 28 to 30 days later.
Also known as: GnRHa
Routine hormone replacement therapy will be used for endometrial preparation before frozen-thawed embryo transfer.
Also known as: HRT
Clinical Pregnancy Rate
Clinical pregnancy is defined as the presence of a gestational sac detected by transvaginal ultrasound 30 ± 3 days after embryo transfer. Clinical pregnancy rate will be calculated as the number of clinical pregnancy cycles divided by the total number of embryo transfer cycles.
Time frame: 30 ± 3 days after embryo transfer
Implantation Rate
Implantation rate will be calculated based on the number of gestational sacs observed by ultrasound relative to the number of embryos transferred.
Time frame: 30 ± 3 days after embryo transfer
Ectopic Pregnancy Rate
Ectopic pregnancy rate will be calculated as the number of ectopic pregnancy cases divided by the total number of embryo transfer cycles.
Time frame: Up to 49 ± 7 days after embryo transfer
Early Spontaneous Abortion Rate
Early spontaneous abortion rate will be calculated as the number of early spontaneous abortions divided by the number of clinical pregnancy cycles.
Time frame: Up to 12 weeks of gestation
Ongoing Pregnancy Rate at 12 Weeks of Gestation
Ongoing pregnancy rate will be calculated as the number of participants with ongoing pregnancy at 12 weeks of gestation divided by the total number of embryo transfer cycles.
Time frame: 12 weeks of gestation
Delivery Rate
Delivery rate will be calculated as the number of participants who deliver divided by the total number of embryo transfer cycles.
Time frame: At delivery, up to study completion
Incidence of Adverse Events After GnRH-a Injection
Adverse events after long-acting GnRH-a injection will be recorded, including hot flashes, headache, sleep disturbance, vaginal bleeding or spotting, night sweats, and mood changes.
Time frame: From first GnRH-a injection to embryo transfer
Plan to share: No
Started Aug 2025 (actual). Primary completion is estimated for Dec 2026, 16 months after the start.
Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 16 months is below that.
Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triptorelin
Li-jun Ding